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ABSTRACT
High-dose chemotherapy followed by blood or marrow transplantation (BMT) is generally considered the best
salvage option for patients with relapsed diffuse large–B-cell non-Hodgkin’s lymphoma (DLCL). The relative
roles for allogeneic and autologous BMT remain controversial. We reviewed the clinical outcome of 183
patients with relapsed DLCL who underwent BMT at Johns Hopkins University in 1985-2001. A total of 45
patients received T-cell–depleted HLA-matched allogeneic bone marrow (allo-BMT), and 138 patients re-
ceived autologous marrow or peripheral blood stem cells (auto-BMT). The allo-BMT recipients had a higher
proportion of patients with chemoresistant disease (P  .004) and had received more chemotherapy before
BMT (P  .02). The auto-BMT recipients were older (P < .001) and were of more advanced-stage disease (P 
.01). The 3-year overall survival (OS) was 23.7% (median survival, 129 days) after allo-BMT and 33.1% (median
survival, 263 days), after auto-BMT (log-rank, P  .17). The 3-year OS for patients with sensitive disease was
51.9% after allo-BMT and 46.2% after auto-BMT (log-rank, P  .38). For patients with resistant disease, the
3-year OS was 12.1% after allo-BMT and 19.1% after auto-BMT (log rank, P  .08). In multivariate analysis,
significant predictors of death were disease sensitivity (hazard rate [HR], 0.3; 95% confidence interval [CI]
0.2-04; P < .001), age >40 years (HR, 2.42; 95% CI, 1.7-3.4; P < .001), and stage at diagnosis (HR, 1.2; 95%
CI, 1.0-1.4; P  .04). The 3-year event-free survival (EFS) for patients with sensitive disease was 52.7% after
allo-BMT and 42.0% after auto-BMT (log-rank, P  .29). For patients with resistant disease, the 3-year EFS
was 6.2% after allo-BMT and 19.4% after auto-BMT (log-rank, P  .1). The 3-year probability of relapse for
chemosensitive patients was 30% after allo-BMT and 46.1% after auto-BMT (log-rank, P  .25). The 3-year
relapse rate in patients with resistant disease was 75.0% after allo-BMT and 69.9% after auto-BMT (log-rank,
P  .58). In multivariate analysis, only disease sensitivity status (HR, 0.4; 95% CI, 0.2-2.1; P < .001) and age
>40 years (HR, 1.7; 95% CI, 1.1-2.9; P .03) appear to have a significant impact on relapse. Transplant-related
mortality (TRM) was the cause of death for 51.1% of allo-BMT recipients and 23.9% of auto-BMT recipients
(P < .001). Mortality from lymphoma was 26.6% in allo-BMT recipients and 43.5% in auto-BMT recipients
(P  .02). Auto-BMT and allo-BMT produced similar survival for patients with relapsed DLCL. For
patients with sensitive disease, allo-BMT seemed to provide longer survival with less relapse; however, this was
achieved at the cost of greater TRM.
© 2006 American Society for Blood and Marrow Transplantation
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cNTRODUCTION
Although many patients with aggressive non-
odgkin’s lymphoma achieve long-term remission after
tandard combination chemotherapy, between 30% and
0% of these patients will eventually relapse [1-4]. Sev- oral studies, including the Parma study, have shown that
or patients with sensitive relapse, high-dose therapy
ollowed by autologous bone marrow transplantation
auto-BMT) provides a better outcome than standard
hemotherapeutic regimens [5-7]. Long-term follow-up
f auto-BMT recipients has shown that a substantial
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I. W. Flinn et al.966umber eventually die of lymphoma [5,8-10]. Further-
ore, for patients with chemotherapy-resistant disease
t relapse, auto-BMT has rarely been able to achieve
ure or long-term remissions [11,12]. Although auto-
MT is widely used, these limitations have led to an
ncreased interest in the use of allogeneic BMT (allo-
MT).
Previous studies have suggested that compared
ith auto-BMT, allo-BMT is associated with a lower
elapse rate. Allo-BMT has the advantage of avoiding
he possible reinfusion of tumor cells and is believed
o provide a beneﬁcial graft versus lymphoma (GVL)
ffect [13]. But the use of allo-BMT is limited by the
ack of donor availability and the risk of graft-versus-
ost disease (GVHD); accordingly, it is often re-
tricted to younger patients. Although T-cell deple-
ion of the allograft may improve the tolerability of
llo-BMT by decreasing the risk of GVHD, it also
ay increase the risk of relapse by blunting the GVL
ffect. Overall survival (OS) has generally been similar
fter auto-BMT and allo-BMT, because a decreased
ncidence of relapse is offset by increased procedure-
elated mortality with allo-BMT [13]. Unfortunately,
revious studies have been limited by small sample
ize and/or heterogeneity of the study populations
9,13-17]. We retrospectively studied only our pa-
ients with pathologically conﬁrmed diffuse large-cell
on-Hodgkin’s lymphoma (DLCL) who had received
llo-BMT or auto-BMT for the treatment of relapsed
isease. Our institutional approach has always been to
rioritize patients under age 60 and with HLA-iden-
able 1. Patient Characteristics
umber of patients
emale
edian age at BMT (range), years
<40 years
>40 years
edian Ann Arbor stage (range) at diagnosis
I
II
III
IV
symptoms
edian no. of prior chemotherapy regimens (range)
<2
>2
edian time until BMT (range), days
isease status at BMT
Sensitive
Resistant
reparative regimen
Bu/Cy
Cy/TBI
Bu/Cy/VP
-HC purge
Sensitive
Resistantical siblings to allo-BMT regardless of disease char-
cteristics. We examined the impact of several factors
n outcome for 183 patients (45 allo-BMT recipients
nd 138 auto-BMT recipients).
ATIENTS AND METHODS
atients
Between 1985 and 2001, a total of 183 consecutive
atients underwent BMT for treatment of relapsed
-cell DLCL at Johns Hopkins University. Only pa-
ients with a pathological report conﬁrming the diag-
osis of DLCL (International Working Formulation
istologic subtypes G and F [18]) were included in the
tudy. Except for patients in whom there was evidence
f transformation from a low-grade histology or a
omponent of an indolent lymphoma subtype, no pa-
ients with DLCL were excluded from the study be-
ause of disease characteristics.
reparative Regimen and Transplantation
The BMT preparative regimen included various
egimens (Table 1), including Bu/Cy (busulfan 1
g/kg orally every 6 hours for 4 days and cyclophos-
hamide 50 mg/kg IV daily for 4 days), Cy/TBI (cy-
lophosphamide 50 mg/kg IV daily for 4 days and
200 cGy given as 300 cGy per day for 4 days with the
ung shielded beginning on the third day of treat-
ent), and Bu/Cy/VP (busulfan as above with etopo-
ide 10-60 mg/kg IV on the ﬁfth day and cyclophos-
llo-BMT Auto-BMT P
45 138
19 47 .4
(18-59) 45 (18-67) <.001
29 61 .02
16 77
(1-4) 3 (1-4) .01
10 24 .02
18 30
8 28
9 56
16 32 .08
(1-4) 1.9 (1-6) .02
36 120 .5
9 18
(91-2362) 372.5 (45-3898) .7
13 71 .004
(71.1%) 67 (48.5%)
17 35 .5
22 91
6 12
NA 36 .2A
36
2
2.1
351
32NA 46
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BMT for Diffuse Large Cell Lymphoma 967hamide 60 mg/kg on the sixth and seventh days). The
reparative therapy was determined by the institu-
ional protocol active at the time and was the same for
oth allo-BMT and auto-BMT recipients.
HLA-matched bone marrow cells from a sibling
onor were used for allo-BMT. No patient in this
eries received mobilized peripheral blood stem cells.
ll allo-BMT patients in this study received a T-cell–
epleted product. The allo-grafts were T-cell de-
leted by counterﬂow centrifugal elutriation, which in
revious studies produced a graft with 4.2  105
D3 cells/kg (range, 3.5-4.9  105 CD3 cells/kg)
nd 1.8  106 CD34 cells/kg (range, 1.7-1.9  106
D34 cells/kg) [19,20]. This process was modiﬁed
n later patients to add back CD34 cells selected
rom the small cell fraction of cells produced by elu-
riation that were previously discarded. This change
nhanced the engraftment characteristics of the graft
nd increased the number of CD34 cells to 3.3 
06 CD34 cells/kg, but it also increased the mean
umber of T-cells in the allograft to 5.5  105 CD3
ells/kg. Autografts were harvested and cryopreserved
efore the BMT preparative therapy was adminis-
ered. After 1997, all autografts consisted of mobilized
eripheral blood stem cells. Before 1994, 82 autolo-
ous marrow grafts were treated with 4-hydroperoxy-
yclophosphamide (4-HC), as described previously [21].
s part of auto-GVHD induction studies, 79 of the
uto-BMT recipients were treated with cyclosporine
CSA) and -interferon (IFN) as described previously
22]. Cell reinfusion occurred 1 day after completing
y/TBI and 1-2 days after completing Bu/Cy or Bu/
y/VP. GVHD prophylaxis consisted of cyclosporine
alone until day 180 post-BMT. Supportive care was
rovided as described previously [23].
efinition and Clinical Outcome
A patient’s disease status at BMT was classiﬁed
ccording to his or her response to the last chemo-
herapeutic intervention before the transplantation
reparative regimen. A patient was categorized as a
ensitive relapse if there was at least a 50% decrease in
easurable disease. A patient were considered a resis-
ant relapse if the disease had progressed, relapsed within
weeks, or exhibited  50% reduction in size after
alvage therapy. The major endpoints were OS, event-
ree survival (EFS), relapse-free survival (RFS), and mor-
ality. OS was deﬁned as the time from the day of BMT
o the day of death or the day of last follow-up. EFS was
eﬁned as the time the day of BMT to disease progres-
ion or death from any cause. RFS was deﬁned as the
ime from the day of BMT to disease progression.
ransplant-related mortality (TRM) was deﬁned as
eath associated with the transplantation procedure
nd not caused by lymphoma. TRM occurring before dhe ﬁrst 100 days posttransplantation was deﬁned as
arly TRM; that occurring after this period, as late
RM. Relapse death was deﬁned as death occurring as
consequence of relapse at any time after BMT.
hose patients in whom the cause of death was un-
nown were censored from TRM and relapse death
nalysis.
tatistics
Event time distributions were estimated using the
aplan and Meier method and compared according to
reatment groups by the log-rank test [24,25]. The
rognostic signiﬁcance of continuously distributed
ariables (ie, age, disease stage, number of prior che-
otherapy regimens) was assessed using the propor-
ional hazards model, with hazard rate (HR) expressed
er unit change [26]. To adjust for the effect of several
rognostic factors simultaneously, the multivariate
roportional hazards model was used. HR  1.0 in-
icates an increased risk for death or relapse in the
resence of the prognostic factor; similarly, HR  1.0
ndicates a lower risk of relapse or death with the
rognostic factor. The Student t-test was used to com-
are set variables between both groups. All P values
eported are 2-sided.
ESULTS
atient Characteristics
A total of 45 patients received allo-BMT, and 138
eceived auto-BMT (Table 1). There was no statisti-
ally signiﬁcant difference between the groups in
erms of sex distribution (P  .4), interval from diag-
osis to BMT (P  .7), presence of B symptoms (P 
08), or type of preparative regimen (P  .5). Allo-
MT recipients were signiﬁcantly younger (median
ge, 36 years; range, 18-59) than auto-BMT recipients
median age, 45; range, 18-67) (P  .001). The Allo-
MT recipients had lower-stage disease at diagnosis
ompared with the auto-BMT recipients (median
tage II vs median stage III, respectively; P  .01). At
ransplantation, resistant disease status was seen in 32
71.1%) of the allo-BMT recipients and in only 67
48.5%) of the auto-BMT recipients (P  .004). The
llo-BMT group had received more previous chemo-
herapy (average of 2.1 regimens per patient) com-
ared with the auto-BMT group (average of 1.9 reg-
mens per patient) (P  .02). Purging of autografts
ith 4-HC was evenly distributed among patients
ith sensitive disease and those with resistant disease
P  .2).
verall Survival
The median OS was 129 days (range, 8-5125 days)
or the allo-BMT group and 263 days (range, 3-6049
ays) for the auto-BMT group. The 3-year OS after
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I. W. Flinn et al.968llo-BMT and auto-BMT was 23.7% and 33.1%, re-
pectively (log-rank, P  .17) (Figure 1). The median
ollow-up for survivors was 1539 days (range, 434-
125 days) for the allo-BMT recipients and 1882 days
range, 395-6049 days) for the auto-BMT recipients
P  .47).
Differences in survival were observed when pa-
ients were stratiﬁed according to transplantation mo-
ality and disease sensitivity status at transplantation
log-rank, P  .001) (Figure 2). For patients with
ensitive disease, the 3-year OS was 51.9% after allo-
MT and 46.2% after auto-BMT (log-rank, P  .38).
lthough the median OS was not reached for the
llograft recipients with sensitive disease, it was 475
ays (range, 3-6049 days) for the auto-BMT recipi-
nts. The median follow-up for survivors with sensi-
ive disease status at BMT was 1539 days (range,
34-5125 days) after allo-BMT and 1998 days (range,
95-6049 days) after auto-BMT (P  .29).
Figure 1. OS afterFigure 2. OS after BMT for relapse DLCL accoPoor survival rates were observed for patients with
hemotherapy-resistant disease at the time of trans-
lantation. With a median OS of 107 days (range,
-4905 days) for the allo-BMT recipients and 160
ays (range, 5-5128 days) for the auto-BMT recipients
nly 12.1% of the allo-BMT recipients and 19.1% of
he auto-BMT recipients were alive at 3 years (log-
ank, P  .08). Median follow-up time for survivors
ith resistant disease was 1093 days (range, 830-4905
ays) after allo-BMT and 1816 days (range, 721-5138
ays) after auto-BMT (P  .87).
In univariate analysis, only disease sensitivity at
ransplant (sensitive vs resistant disease) HR, 0.4; 95%
onﬁdence interval [CI], 0.3-0.5; P  .001), age (40
ears old vs 40 years old: HR, 1.9; 95% CI, 1.3-2.6;
 .001), and number of prior chemotherapy regi-
ens (2 vs 2 treatments: HR, 1.6; 95% CI, 1.0-
.4; P  .05) were shown to have a statistically signif-
cant effect on mortality (Table 2). This was
for relapse DLCL.rding to disease sensitivity status at BMT.
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BMT for Diffuse Large Cell Lymphoma 969onﬁrmed in multivariate analysis (Table 3) in which
redictors of death were disease status (sensitive vs
esistant disease: HR, 0.3; 95% CI, 0.2-0.4; P  .001),
nd patient age (40 years old vs 40 years old: HR,
.4; 95% CI, 1.7-3.4; P  .001). In the multivariate
nalysis, stage at diagnosis was also found to be a
redictor of death (stage as a continuous value: HR,
.2; 95% CI, 1.0-1.4; P  .04). The transplantation
reparative regimen had no impact on survival (data
ot shown).
vent-Free Survival
With a median follow-up time of 95 days (range,
-5125 days) and 155 days (range, 3-6049 days), the
robability of a patient surviving 3 years without death
r relapse was 19.1% after allo-BMT and 30.9% after
uto-BMT (P  .2). Disease sensitivity status at trans-
lantation had a signiﬁcant impact on the EFS (log
ank, P  .001) (Figure 3). For patients with sensitive
elapse, the probability of 3-year EFS was 52.7% after
llo-BMT and 42.0% after auto-BMT (log rank, P 
29). The median EFS time was not reached for the
llo-BMT recipients and it was 308 days (range,
-6049 days) for autograft recipients. In patients with
esistant disease, with a median follow-up time of 90
range, 8-4905 days) for allo-BMT recipients and 10
ays (range, 50-3898 days) for auto-BMT recipients,
he probability of 3-year EFS was 6.2% and 19.4%,
espectively (log rank, P  .1).
elapse-Free Survival
With a median follow-up time of 253 days (range,
5-5125 days) after allo-BMT and 242 days (range,
3-6049 days) after auto-BMT, 55% and 48.1% of
atients relapsed in the ﬁrst 3 years, respectively (P 
85). The last patient to relapse after allo-BMT was at
3 months, whereas auto-BMT patients continued to
elapse out to 4 years.
For patients with sensitive disease status at BMT,
he 3-year probability of relapse was 30.0% after allo-
able 2. Predictor of Death in Univariate Analysis
Predictor HR 95% CI P
llo-BMT* 1.3 0.9-1.9 .21
ensitive disease† 0.4 0.3-0.5 <.001
emale‡ 1.0 0.7-1.4 .9
onth to BMT 1.0 0.9-1.0 .5
ge (>40 years) 1.9 1.3-2.6 <.001
tage at diagnosis§ 1.1 0.9-1.2 .5
2 prior chemotherapy regimens 1.6 1.0-2.4 .05
VHD 1.4 0.9-2.1 .1
Versus auto-BMT.
Versus resistant disease.
Versus male.
Continuous.MT and 46.1% after auto-BMT (log-rank, P  .25).
She median RFS time was not reached by the allo-
MT recipients; it was 1250 days (range, 59-6049
ays) for the auto-BMT recipients. For patients with
esistant disease status, the 3-year probability of re-
apsing was 75.0% for allo-BMT recipients and 69.9%
or auto-BMT recipients, and the median RFS time
as 95 days (range, 55-4905 days) and 123 days
range, 23-5138 days), respectively (log rank, P  .58)
Figure 4).
In univariate analysis (Table 4), statistically signif-
cant predictors of relapse included disease sensitivity
o chemotherapy (sensitive vs resistant disease: HR,
.4; 95% CI, 0.2-0.7; P  .001) and number of prior
hemotherapy regimens (2 vs 2: HR, 1.9; 95% CI,
.0-3.7; P  .05). In multivariate analysis (Table 5),
nly disease status (sensitive vs resistant disease: HR,
.4; 95% CI, 0.2-2.1; P  .001) and age 40 years
HR, 1.7; 95% CI, 1.1-2.9; P  .03) were found to be
igniﬁcant predictors of relapse. Although GVHD did
ppear to increase the risk of relapse in univariate
nalysis, this did not appear to be the case in multi-
ariate analysis.
ransplant-Related Mortality
There was a statistically signiﬁcant difference in
RM between the allo-BMT recipients (51.1%) and the
uto-BMT recipients (23.9%) (P  .001) (Table 6).
atients with resistant disease at transplantation were
ore likely to die from transplant-related complica-
ions if they received an allo-BMT (62.5%) than if
hey received an auto-BMT (31.3%) (P  .02); how-
ver, there was no statistical difference in mortality for
atients with sensitive relapse (P  .3). TRM in the
rst 100 days post-BMT was 33.3% for the allo-BMT
ecipients and 17.4% for the auto-BMT recipients
P .03). After 100 days, TRM remained signiﬁcantly
igher for the allo-BMT recipients (17.8% vs 6.5%
or auto-BMT; P  .001). Multiorgan failure and
nfections were the most frequent causes of death in
he early posttransplantation period for both groups of
atients. GVHD was a signiﬁcant contributing factor
or death in the allo-BMT group (5 patients with
cute GVHD and 11 with chronic GVHD in the
llo-BMT recipients vs 1 patient with acute and none
ith chronic GVHD in the autograft recipients).
ore patients died of relapse in the auto-BMT group
43.5% for the auto-BMT patients vs 26.6% for the
llo-BMT patients; P  .02).
able 3. Predictor of Death in Multivariate Analysis
Predictor HR 95% CI P
ensitive disease 0.3 0.2-0.4 <.001
ge (>40 years) 2.4 1.7-3.4 <.001
llo-BMT 1.2 0.8-1.9 .3
tage at diagnosis (continuous) 1.2 1.0-1.4 .04
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I. W. Flinn et al.970raft-Versus-Host Disease
In the allo-BMT group, acute GVHD was diag-
osed in 17 patients and chronic GVHD in 11 pa-
ients. The remaining patients had no evidence of
VHD. In the presence of GVHD, after allo-BMT
or sensitive relapse, the median OS was 1036 days
range, 356-5125 days); median OS was not reached
or the whole group with sensitive disease. All of the
atients with chronic GVHD eventually died of
VHD or other causes. For the patients with resistant
isease, GVHD after allo-BMT was associated with a
edian OS of 111 days (range, 18-1458 days); median
S was 107 days (range, 8-4905) days for the whole
roup with resistant disease. Autologous GVHD had
o statistically signiﬁcant impact on survival or death
data not shown).
Figure 3. Event-free survival after BMT for relapFigure 4. Relapse-free survival after BMT for relapse DLISCUSSION
Although the efﬁcacy of BMT for patients with
LCL is well established, the relative utility of using
utografts versus allografts is less clear. Previous stud-
es of patients with lymphomas have shown that both
llo-BMT and auto-BMT provide comparable OS.
ndependent prognostic factors have included perfor-
ance status, stage, international prognostic score,
ex, age, lactate dehydrogenase level, disease chemo-
herapy sensitivity status at the time of transplanta-
ion, and whether pretransplantation or posttrans-
lantation radiation therapy had been administered
10,12,27-29]. These conclusions have often been
rawn from the results of small retrospective studies
f patients with often various types of diseases [9,13-
L according to disease sensitivity status at BMT.CL according to disease sensitivity status at BMT.
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BMT for Diffuse Large Cell Lymphoma 9717]. The present study represents an analysis of a
ingle-institution set of patients who underwent allo-
MT or auto-BMT for relapsed DLCL.
Overall, there were no statistically signiﬁcant dif-
erences in OS and EFS between the allo-BMT and
uto-BMT recipients. Although there is a relatively
ncreased TRM after allo-BMT, a higher relapse rate
fter auto-BMT probably accounts for the lack of
ifference in OS between these 2 groups. These ﬁnd-
ngs are in agreement with previous studies [14-16].
owever, TRM in autograft recipients is higher than
as been reported in some other series [12,15-17]. It is
nclear what can account for this difference, but it
ay be secondary to posttransplantation adjuvant
herapy, such as auto-GVHD induction or patient
election.
For patients with sensitive disease, there was a
rend for improved survival at 3-years after allo-BMT
51.9%) in comparison to auto-BMT (46.2%). The
-year EFS for these patients was 52.7% after allo-
MT and 42.0% after auto-BMT. These results sup-
ort the notion that allo-BMT is a reasonable option
or patients at increased risk of relapse after BMT. It
s clear, however, that even allo-BMT is insufﬁcient
or patients with resistant disease at the time of BMT,
n whom very poor outcomes were seen regardless of
hat type of graft was used (3-year OS 12.1% after
llo-BMT and 19.1% after auto-BMT). Allo-BMT
as particularly ineffective for these patients, with
nly 6.2% having a 3-year EFS (vs 3-year EFS of
9.4% after auto-BMT). The poor outcome in pa-
ients with chemotherapy-resistant disease regardless
f the graft’s origin seems to be the result of both a
igh TRM and a high relapse rate. These ﬁndings are
able 4. Predictor of Relapse in Univariate Analysis
Predictor HR 95% CI P
llo-BMT* 1.3 0.7-2.3 .3
ensitive disease† 0.4 0.2-0.7 <.001
emale‡ 0.7 0.4-1.2 .3
onth to BMT 1.0 0.9-1.0 .6
ge (>40 years) 1.4 0.9-2.3 .2
tage at diagnosis§ 0.9 0.7-1.1 .2
2 prior chemotherapy regimens 1.9 1.0-3.7 .05
VHD 1.8 1.0-3.2 .04
Versus auto-BMT.
Versus resistant disease.
Versus male.
Continuous.
able 5. Predictor of Relapse in Multivariate Analysis
Predictor HR 95% CI P
ensitive disease 0.4 0.2-2.1 <.001
ge (>40 years) 1.7 1.1-2.9 .03
llo-BMT 1.1 0.7-2.1 .6F
tage at diagnosis (continuous) 0.9 0.8-1.2 .7n agreement with previously published reports [14-
6]. The toxicity associated with BMT in these pa-
ients highlights the need for new approaches in this
atient population.
In patients with sensitive disease, the relapse rate
or allo-BMT recipients was lower than that in auto-
MT recipients, indicating a possible GVL effect. It is
oteworthy that all patients who developed chronic
VHD ultimately died, which likely attenuates the
eneﬁt from GVL. As noted earlier, the GVL effect
lone is insufﬁcient to improve survival in patients
ith resistant disease. All of the allo-BMT patients in
his study received a T-cell–depleted graft. This
ethodology results in a relative depletion of T cells,
lthough a substantial number of T cells are still
ncluded in the allo-graft. This approach may preserve
he GVL effect, albeit at in increased risk of GVHD
han for a fully T-cell–depleted graft. Approaches that
eparate the GVL effect from GVHD, such as vac-
ines, have signiﬁcant potential for these patients.
Conﬁrming the results of other studies, we found
o difference overall in OS and EFS between allo-
MT and auto-BMT recipients. Response to conven-
ional chemotherapy pretransplantation appears to be
ighly predictive of outcome for both allo-BMT and
uto-BMT recipients. Whether it can be concluded
hat allo-BMT is superior to auto-BMT for chemo-
ensitive disease remains questionable. The trend for
igher and later relapses in patients with sensitive
elapse receiving auto-BMT compared to those re-
eiving allo-BMT suggests that allo-BMT should be
onsidered for selected patients with relapsed DLCL.
able 6. Mortality
Allo-BMT
(n  45)
Auto-BMT
(n  138) P
otal TRM 23 (51.1%) 33 (23.9%) <.001
Sensitive disease 3 (23.0%) 12 (16.9%) .3
Resistant disease 20 (62.5%) 21 (31.3%) .02
100 days TRM 15 (33.3%) 24 (17.4%) .03
Multiorgan failure 9 16
Infection/sepsis 5 12
Veno-oclusive disease (VOD) 4 3
Myocardial infarction 1 2
GVHD 5 1
Hemmorhage 1 1
Lymphoma 1 4
100 days TRM 8 (17.8%) 9 (6.5%) <.001
Multiorgan failure 3 7
Infection/sepsis 2 5
Hemmorhage 3 0
Cerebrovascular accident 1 0
GVHD 11 0
Lymphoma 4 7
elapse death 12 (26.6%) 60 (43.5%) .02
Sensitive disease 3 29 .33
Resistant disease 9 31 .08
nknown cause of death 0 7or patients with chemorefractory disease for whom
m
d
B
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
I. W. Flinn et al.972inimal or modest results are expected from the high-
ose therapy, novel therapies in conjunction with
MT are needed.
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